Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
about
Assessment of vaccine candidates for persons aged 50 and older: a review.Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 yearsClinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacySeropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.Reconstruction of H3N2 influenza virus based virosome in-vitro.Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.Biology of immune responses to vaccines in elderly persons.Epaxal: a virosomal vaccine to prevent hepatitis A infection.The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adultsViral hepatitis in the elderly.Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy.Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.Vaccination in the elderly: what can be recommended?An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Recent advances in the preparation and application of multifunctional iron oxide and liposome-based nanosystems for multimodal diagnosis and therapy.Guidelines for the prevention of travel-associated illness in older adults.Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression.Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults.Q56931621
P2860
Q34668826-4F17767D-F901-48E8-A246-8C1AB81F23ACQ35066156-0B989C15-0FDF-40AF-BDC1-D5A3AF8F1CCDQ35679856-B97FA0F3-D6C1-4F0C-8221-B5F3D3D4CF37Q35833600-76F1A19D-87B7-4CF5-9A1C-0CC922EAAAEEQ36967974-ABC88A13-93D7-445C-ACEE-01DFD517957BQ36968260-81B440DF-1385-4A83-A60A-00E665C8F7E0Q37150299-190BB841-E388-400C-B47F-CA9E7CCA780EQ37290088-51F59C94-4956-44D3-BFEE-3FB40986CEE8Q37418883-9B0B34A5-E800-49DC-9115-AAA945050E88Q37980037-601B5AAD-737A-4BFA-8223-16773D79A0EDQ38123458-9DF97F94-33E5-4956-A1B5-B025A58E88BCQ38186768-D5D5527C-6FC0-405D-A26C-9672A20AF42CQ38220158-9FE052E0-179A-408B-BE4F-3CE353EE7FB8Q38971243-2E78FEC4-00A5-4A8A-801D-32187A59BA3EQ39030223-A9818552-B9D5-41EF-B773-6A40B09CE458Q40061282-DC6AF2FE-C584-4ECE-A815-194167B66142Q42249242-17100ED6-6D8A-4878-8FD8-6381CB415DFAQ55006232-DE220FD5-0680-4D93-8B65-054BEFF137EFQ56931621-239B207D-0AFC-49BF-B615-541471F85790
P2860
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
@en
Immunogenicity and safety of a virosomal hepatitis A vaccine
@nl
type
label
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
@en
Immunogenicity and safety of a virosomal hepatitis A vaccine
@nl
prefLabel
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
@en
Immunogenicity and safety of a virosomal hepatitis A vaccine
@nl
P2860
P1476
Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
@en
P2093
Christian Herzog
Valérie D'Acremont
P2860
P356
10.1111/J.1708-8305.2006.00001.X
P577
2006-03-01T00:00:00Z